These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33035097)

  • 1. Sacral neuromodulation system for treating refractory overactive bladder.
    Phillips A
    Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance.
    Poole RL; Dale M; Morgan H; Oladapo T; Brookfield R; Morris R
    Appl Health Econ Health Policy; 2022 May; 20(3):305-313. PubMed ID: 34964090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
    Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience.
    Elterman DS
    Neurourol Urodyn; 2018 Feb; 37(S2):S1-S8. PubMed ID: 29336078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder.
    Albabtain M; Chughtai B; Cho A; Elterman D
    Ther Deliv; 2021 May; 12(5):353-362. PubMed ID: 33821666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
    McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
    J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
    Parnell BA; Howard JF; Geller EJ
    Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sacral neuromodulation for refractory overactive bladder].
    van Ophoven A
    Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
    Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
    Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
    Girtner F; Burger M; Mayr R
    Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
    Fletcher N
    Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacral neuromodulation: Rechargeable versus non-rechargeable device. What would the patient preferences be in France?
    Gamé X; Ruffion A; Cornu JN; Phé V; Peyronnet B; Perrouin-Verbe MA; Aublant C; Adé A; Chartier-Kastler E
    Prog Urol; 2022 Sep; 32(10):672-680. PubMed ID: 35752523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of neuromodulation in patients with neurogenic overactive bladder.
    Lay AH; Das AK
    Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
    Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SACRAL NEUROMODULATION IN TREATING OVERACTIVE BLADDER PATIENTS - FIRST-TIME APPLICATION IN CROATIA.
    Bakula M; Hauptman D; Hudolin T; Škegro SN; Tudor KI; Bakula B; Kaštelan Ž
    Acta Clin Croat; 2023 Jul; 62(Suppl2):143-147. PubMed ID: 38966014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.